



GLENN HEGAR TEXAS COMPTROLLER OF PUBLIC ACCOUNTS

MEMORANDUM

December 30, 2024

TO: Internal Memo

FROM: Katy Fallon-Brown, Director of Texas Opioid Abatement Fund Council

RE: **FY 2022-2025 Revenue and Expenditures from Settlement Agreements/Court Orders**

This memorandum reflects funds received and available from the settlement agreements or court orders as of December 30, 2024, totaling **\$ 640,548,135.37** net attorney fees. **These amounts do not reflect the \$75,000,000 that the Council has previously obligated for statewide grants nor commitments for future grant issuance plans.**

Year	Source	Amount	Description
FY 2022 – Jan. 2022	McKinsey	4,540,343.02	Opioid Abatement Account/ State share
FY 2022 – April 2022	McKinsey	197,362.26	Opioid Abatement Account/ State share
FY 2023 – May 2023	McKinsey	246,702.83	Opioid Abatement Account/ State share; Unappropriated
FY 2022 – March 2022	J&J/Jansen	39,492,329.75	Opioid Abatement Account/ State share
FY 2022 – June 2022	Endo	8,373,408.75	Opioid Abatement Account/ State share
FY 2022 – June 2022	Teva	4,730,437.50	Opioid Abatement Account/ State share
FY 2023 – Aug. 2023	Teva	750,000.0	Opioid Abatement Account/ State share; Unappropriated
FY 2023 – Jan. 2023	Global Opioid Distributors	11,820,474.74	Opioid Abatement Account/ State share
FY 2023 – June 2023	Mallinckrodt	1,444,293.01	Opioid Abatement Account/ State share; Unappropriated
FY 2024 – Nov. 2023	Global Opioid Distributors	7,633,192.47	Opioid Abatement Account/ State share; Unappropriated
FY 2024 – Nov. 2023	Mallinckrodt	1,699,168.24	Opioid Abatement Account/ State share; Unappropriated
FY 2024 – Feb. 2024	Walmart	8,996,224.64	Opioid Abatement Account/ State share; Unappropriated
FY 2024 – April 2024	Global Opioid Distributors	4,218,578.02	Opioid Abatement Account/ State share; Unappropriated

<i>Year</i>	<i>Source</i>	<i>Amount</i>	<i>Description</i>
FY 2024 – April 2024	Publicis Health	3,125,359.49	Opioid Abatement Account/ State share; Unappropriated
FY 2024 - Aug. 2024	Global	9,570,280.87	Opioid Abatement Account/ State share; Unappropriated
FY 2025 - Sept. 2024	Walgreens	4,257,067.66	Opioid Abatement Account/ State share; Unappropriated
FY 2025 - Sept. 2024	Walmart	9,620,595.28	Opioid Abatement Account/ State share; Unappropriated
FY 2025 - Sept. 2024	CVS	1,681,994.71	Opioid Abatement Account/ State share; Unappropriated
FY 2025 - Oct. 2024	Allergan	3,613,260.18	Opioid Abatement Account/ State share; Unappropriated
FY 2025 - Dec. 2024	Interest	2,019.27	Opioid Abatement Account/ State share; Unappropriated
Total \$ 126,013,092.69			

<i>Year</i>	<i>Source</i>	<i>Amount</i>	<i>Description</i>
FY 2022 – June 2022	Endo	38,575,907.50	Trust fund share
FY 2022 – June 2022	Teva	22,075,375.00	Trust fund share
FY 2023 – Aug. 2023	Teva	3,500,000.00	Trust fund share
FY 2022 – Oct. 2022	J&J/Jansen	164,004,732.50	Trust fund share
FY 2023 – Jan. 2023	Global Opioid Distributors	25,325,280.96	Trust fund share
FY 2023 – June 2023	Mallinckrodt	6,740,034.03	Trust fund share
FY 2024 – Sept. 2023	McKinsey	22,819,947.11	Trust fund share
FY 2024 – Nov. 2023	Global Opioid Distributors	21,222,124.39	Trust fund share
FY 2024 – Nov. 2023	Mallinckrodt	7,929,451.81	Trust fund share
FY 2024 – Feb. 2024	Walmart	41,982,381.67	Trust fund share
FY 2022 – 2025	Interest	31,823,684.53	Trust fund share interest
FY 2023 – Nov. 2022	Distribution	(5,000,000.00)	Texas Access to Justice Foundation Payment

<i>Year</i>	<i>Source</i>	<i>Amount</i>	<i>Description</i>
FY 2024 – Oct. 2023	Distribution	(493,000.00)	CPA Administrative Allocation for Personnel, Travel, Benefits and Contracts
FY 2024 – April 2024	Global Opioid Distributors	19,686,697.44	Trust fund share
FY 2024 – April 2024	Publicis Health	14,585,010.94	Trust fund share
FY 2024 - Aug. 2024	Distribution Return	493,000.00	CPA Administrative Allocation for Personnel, Travel, Benefits and Contracts
FY 2024 - Aug. 2024	Global Opioid Distributors	30,198,894.76	Trust fund share
FY 2024 – Aug. 2024	Distribution	(65,770,854.13)	Hospital District Allocation
FY 2025 - Sept. 2024	Walmart	44,896,111.26	Trust fund share
FY 2025 - Sept. 2024	CVS	7,849,308.62	Trust fund share
FY 2025 - Sept. 2024	Walgreens	19,866,315.75	Trust fund share
FY 2025 - Oct. 2024	Allergan	16,861,880.87	Trust fund share
Total \$ 469,172,285.01			

<i>Year</i>	<i>Source</i>	<i>Amount</i>	<i>Description</i>
FY 2022 – June 2022	Endo	7,873,408.75	Subdivision share (Municipalities/counties)
FY 2022 – June 2022	Teva	4,730,437.50	Subdivision share (Municipalities/counties)
FY 2023 – Aug. 2023	Teva	750,000.00	Subdivision share (Municipalities/counties)
FY 2022 – Oct. 2022	J&J/Jansen	30,166,610.48	Subdivision share (Municipalities/counties)
FY 2023 – Jan. 2023	Global Opioid Distributors	3,940,050.62	Subdivision share (Municipalities/counties)
FY 2023 – March 2023	Distribution	(47,088,165.36)	Subdivision share (Municipalities/counties)
FY 2023 – June 2023	Mallinckrodt	1,444,293.01	Subdivision share (Municipalities/counties)
FY 2024 – Sept. 2023	McKinsey	4,027,049.49	Subdivision share (Municipalities/counties)
FY 2024 – Nov. 2023	Global Opioid Distributors	3,938,138.54	Subdivision share (Municipalities/counties)

<i>Year</i>	<i>Source</i>	<i>Amount</i>	<i>Description</i>
FY 2024 – Nov. 2023	Mallinckrodt	1,699,168.24	Subdivision share (Municipalities/counties)
FY 2024 – Feb. 2024	Walmart	8,996,224.64	Subdivision share (Municipalities/counties)
FY 2022 – 2025	Interest	1,924,256.28	Subdivision share interest (Municipalities/counties)
FY 2024 – April 2024	Global Opioid Distributors	4,218,578.02	Subdivision share (Municipalities/counties)
FY 2024 – April 2024	Publicis Health	3,125,359.49	Subdivision share (Municipalities/counties)
FY 2024 – April 2024	Distribution	(9,160,657.93)	Subdivision share (Municipalities/counties)
FY 2024 - Aug. 2024	Global Opioid Distributors	4,207,105.37	Subdivision share (Municipalities/counties)
FY 2025 - Sept. 2024	Walmart	9,620,595.28	Subdivision share (Municipalities/counties)
FY 2025 - Sept. 2024	CVS	1,681,994.71	Subdivision share (Municipalities/counties)
FY 2025 - Sept. 2024	Walgreens	4,257,067.66	Subdivision share (Municipalities/counties)
FY 2025 - Oct. 2024	Allergan	3,613,260.18	Subdivision share (Municipalities/counties)
Total \$ 43,964,774.97			

<i>Year</i>	<i>Source</i>	<i>Amount</i>	<i>Description</i>
FY 2023	McKinsey	1,397,982.70	Unappropriated General Revenue
Total \$ 1,397,982.70			